                               NIH Public Access
                               Author Manuscript
                               Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                           Published final edited form 
NIH-PA Author Manuscript




                            Mol Biochem Parasitol. 2011 January ; 175(1): 21–29. doi:10.1016/j.molbiopara.2010.08.005.



                           Identification inhibitors putative malaria drug targets
                           novel antimalarial compounds
                           Gregory J. Crowthera, Alberto J. Napulia, James H. Gilliganb, Kerstin Gagaringb, Rachel
                           Borboab, Carolyn Francekb, Zhong Chenb, Eleanor F. Dagostinob, Justin B. Stockmyerb, Yu
                           Wangb, Philip P. Rodenbougha, Lisa J. Castanedaa, David J. Leiblya, Janhavi Bhandaria,
                           Michael H. Gelba, Achim Brinkerb, Ingo Engelsb, Jennifer Taylorb, Arnab K. Chatterjeeb,
                           Pascal Fantauzzic, Richard J. Glynneb, Wesley C. Van Voorhisa, Kelli L. Kuhenb

                           aUniversity Washington, Seattle, WA, USA b Genomics Institute Novartis Research
                           Foundation (GNF), San Diego, CA, USA c Medicines Malaria Venture, Geneva, Switzerland

                           Abstract
NIH-PA Author Manuscript




                                 efficacy marketed antimalarial drugs compromised evolution parasite
                                 resistance, underscoring urgent need new drugs new mechanisms action.                                  taken high-throughput approach identifying novel antimalarial chemical inhibitors
                                 prioritized drug targets P. falciparum, excluding targets inhibited currently
                                 used drugs. screen commercially available libraries identified 5,655 low molecular weight
                                 compounds inhibit growth P. falciparum cultures EC50 values 1.25 μM.                                  compounds tested 384- 1536 biochemical assays activity                                  Plasmodium enzymes: adenylosuccinate synthetase (AdSS), choline kinase (CK), deoxyuridine
                                 triphosphate nucleotidohydrolase (dUTPase), glutamate dehydrogenase (GDH), guanylate kinase
                                 (GK), N-myristoyltransferase (NMT), orotidine 5′-monophosphate decarboxylase (OMPDC),
                                 farnesyl pyrophosphate synthase (FPPS) S-adenosylhomocysteine hydrolase (SAHH).                                  enzymes selected using TDRtargets.org, believed excellent potential drug
                                 targets based criteria likely essentiality, druggability, amenability high-
                                 throughput biochemical screening. targets inhibited                                  antimalarial scaffolds potential use drug development, target validation
                                 studies exploration P. falciparum biochemistry biology.
NIH-PA Author Manuscript




                           Keywords
                                 target-based drug development; enzyme activity assays; antimalarial compounds


                           1. Introduction
                                             Approximately 3 billion people, half world’s population, live risk regions                                              malaria infection. leads 250 million malaria cases year nearly 

                           © 2010 Elsevier B.V. rights reserved.
                           Corresponding author: K.L.K., Genomics Institute Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San
                           Diego CA 92121, USA; phone: 858-812-1819; fax: 858-812-1819; kkuhen@gnf.org.
                           Publisher's Disclaimer: PDF file unedited manuscript accepted publication. service                            customers providing early version manuscript. manuscript undergo copyediting, typesetting, review                            resulting proof published final citable form. note production process errors                            discovered affect content, legal disclaimers apply journal pertain.
                            Crowther et al.                                                                                             Page 2


                                             million deaths (World Malaria Report,  2009,
                                             http://www int/malaria/world_malaria_report_2009 index.html). etiologic agent
                                             Plasmodium falciparum organism responsible majority deaths NIH-PA Author Manuscript




                                             malaria, 90  occur Africa 85  children age 5.
                                             presence widespread drug resistance hampering effectiveness                                              available drug arsenal [1–6] notable exception artemisinin-based derivatives.
                                             Artemisinin-based combination therapies (ACT) recommended line treatments
                                             falciparum malaria countries endemic disease [7]. ACT remains
                                             effective, recent concerns efficacy artemisinin-based derivatives                                              declined Thai-Cambodian border [8–10]. Potential clinical resistance closely
                                             monitored areas Southeast Asia artemisinin used monotherapy                                              decades antimalarial drug resistance previously developed. potential
                                             development artemisinin resistance parasite loss ACT crisis,                                              ACTs recommended worldwide new agents currently phase 3 clinical
                                             trials based ACT. battle fight malaria, introduction new drugs novel
                                             mechanisms action essential.

                                             Data essentiality putative drug targets Plasmodium growth limited                                              individual genes tested gene disruption studies [11–19]. 
                                             chemical inhibition target genetic essentiality does translate                                              pharmacological efficacy pathogen [20], genetic data essentiality
NIH-PA Author Manuscript




                                             available comprehensive genome-wide dataset Plasmodium. Inhibition P.
                                             falciparum replication chemical inhibition potential drug targets  instead,
                                             provide chemical validation targets. end, undertook effort provide
                                             chemical tools explore biology prioritized Plasmodium targets, provide                                              starting point chemical validation targets. developed biochemical assays                                              test enzymatic activity prioritized targets. set compounds                                              pre-annotated having inhibitory activity P. falcpiarum proliferation erythrocytes
                                             tested inhibitory activity biochemical assays. reasoned                                              screening compounds known cell-based activity  
                                             address issues plagued biochemical approaches. include
                                             cellular permeability, efflux metabolism small-molecule inhibitors.

                                             screened GNF’s non-proprietary compound collection identified subset                                              5,655 compounds potent inhibitory activity P. falciparum growth vitro                                              described [21]. compounds non-proprietary available
                                             commercially, facilitating broad exploration mechanism action academic
                                             community. structures compounds available                                              http://www.ebi.ac.uk/chembldb/ http://www.TDRtargets.org/. included NIH-PA Author Manuscript




                                             dataset dose-response data activity strains P. falciparum, 3D7 W2,                                              EC50 values, cytotoxicity information human hepatocellular carcinoma cell
                                             line Huh7, measure promiscuity compounds historical high-
                                             throughput screens conducted GNF. available, compounds tested 
                                             ordered powders supplier. collection screened high-throughput
                                             biochemical assays Plasmodium enzymes considered promising drug
                                             targets based data compiled TDRtargets.org [22] literature data.                                              results target-based biochemical screens discussed  Notably                                              identified chemical inhibitors 6 9 targets tested sub-library                                              thousand compounds, preselected cellular activity.




                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                              Page 3


                              2. Materials methods
                              2.1. Identification antimalarial compounds
NIH-PA Author Manuscript




                                             high-throughput screen GNF’s non-proprietary compound collection performed
                                             using erythrocyte-based P. falciparum strain 3d7 infection assay essentially described
                                             [21]. Compounds screened 1.25 μM; hits inhibiting growth                                              ≥50  reconfirmed dose-response format determine EC50 values, cellular
                                             cytotoxicity (quantified CC50) assessed Huh7 hepatocellular carcinoma cell
                                             line. Compounds selectivity index <5 (CC50/EC50) excluded                                              consideration, compounds quench fluorescence. Reconfirmed hit
                                             compounds (5,655 total) ordered powders 3,086 compounds                                              available purchase suppliers.

                              2.2. Target selection
                                             selecting enzymes screen (Table 1), employed TDRtargets.org [22]                                              sources identify Plasmodium enzymes candidates compound screening using                                              following criteria:  enzyme likely required survival parasite; ii)                                              enzyme small-molecule binding pocket exploited drug-like
                                             molecule inhibit enzymatic activity; iii) exploitable differences                                              parasite human enzymes pathways belong drug NIH-PA Author Manuscript




                                             developed minimal adverse effects host; iv) enzyme amenable                                              recombinant expression  precedent selected targets [23–30];                                              v) enzymatic activity measured high-throughput format. criteria                                              focused especially  iv, v druggability (ii) selectivity (iii) currently
                                             difficult predict.  example  difluoromethylornithine inhibits                                              human T. brucei ornithine decarboxylases, selectively kills T. brucei cells,
                                             apparently rapid turnover human enzyme [31].)                                              enzymes chosen criteria adenylosuccinate synthetase (AdSS), choline kinase
                                             (CK), deoxyuridine triphosphate nucleotidohydrolase (dUTPase), farnesyl pyrophosphate
                                             synthase (FPPS), glutamate dehydrogenase (GDH), guanylate kinase (GK), N-
                                             myristoyltransferase (NMT), orotidine 5′-monophosphate decarboxylase (OMPDC), S-
                                             adenosylhomocysteine hydrolase (SAHH).

                              2.3 Expression purification recombinant Plasmodium proteins
                                             Recombinant histidine-tagged enzymes Plasmodium falciparum P. vivax                                              expressed Escherichia coli purified immobilized metal affinity chromatography,
                                             essentially described previously [32].
NIH-PA Author Manuscript




                              2.4 Biochemical assay details
                                             Specific activities enzymes studied reported previously [33],                                              comparisons literature values possible.

                                             Enzyme activity assays miniaturized optimized 1536 plates test
                                             compounds screened dose-response format 12 points ½-log serial dilutions
                                             (0.0005 – 100 μM), exception SAHH, screened single-point format
                                             384 plates. Incubations room temperature unless noted.                                              reactions included final [DMSO] 1 . initial collection antimalarial compounds
                                             available set DMSO solutions pre-existing GNF compound library
                                             (available formats: 5,655 compounds, 1536 dose-response format; 5,543 compounds,
                                             384 single point format), 6 targets screened using collections (Table 3).
                                             original stocks antimalarial compounds depleted, remaining
                                             targets (FPPS, dUTPase, NMT) screened using DMSO solutions reconstituted

                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                             Page 4


                                             3,086 compounds available repurchasing time screens. Hits                                              reconfirmed using ordered purified powders available vendor tested
                                             dose-response format.
NIH-PA Author Manuscript




                                             Chemical reactions detection strategies enzyme shown Table 2;
                                             additional details noted  general, assay concentrations substrates                                              approximately 3 times respective Km’s. Compounds, general, added enzyme
                                             buffer reagents 10 minutes prior initiation reaction addition substrate.                                              compounds hit multiple target-based assays triaged lack specificity
                                              e., likely false positives) included final hit list (Supplementary Table S1).

                                             AdSS assayed buffer 50 mM Tris, pH 7.0, 5 mM DTT, 0.1  BSA, 0.001 
                                             Tween-20, 2.5 mM MgCl2. Final concentrations 500 ng/mL AdSS (10 nM), 30
                                             μM GTP, 60 μM IMP, 1 mM aspartate. Incubation time 40 minutes,                                              GDP produced AdSS detected Transcreener GDP detection mix (Cisbio),
                                             used according manufacturer’s instructions. Homogeneous time-resolved fluorescence
                                             (HTRF) GDP produced monitored excitation 337 nm dual emission                                              620 665 nm.

                                             CK assayed buffer 100 mM HEPES, pH 7.5, 150 mM NaCl 1 mM
                                             MgCl2. Final concentrations 312.5 ng/mL CK (5 nM), 10 μM ATP, 280 μM
NIH-PA Author Manuscript




                                             choline. Incubation time 30 minutes, ADP produced CK                                              detected Transcreener ADP detection mix (Cisbio), AdSS.

                                             dUTPase assayed buffer 25 mM MOPS, pH 8.0, 10 mM KCl, 1.25 mM
                                             MgCl2, 0.1 mg/mL BSA, 0.005  Triton X 20  glycerol. Final concentrations 2
                                             ng/mL dUTPase (97 pM) 14 μM dUTP. Incubation time 30 minutes. Production                                              PPi monitored PPiLight kit (Lonza) conversion ATP measurement                                              luminescent signal corresponding [ATP]. PPi detection mix diluted 1:4                                              reaction buffer prior use.

                                             FPPS assayed buffer 50 mM HEPES, pH 7.5, 0.625 mM MgCl2, 1 mM
                                             NaCl, 0.25 mM TCEP, 5  BSA, 10  glycerol, 0.01  Triton X-100. Final
                                             concentrations 1.3 μg/mL FPPS (45 nM), 25 μM geranyl diphosphate, 25 μM
                                             isopentenyl diphosphate. Incubation time 30 minutes. Production PPi monitored
                                             PPiLight kit (Lonza), dUTPase.

                                             GDH assayed buffer 100 mM Tris, pH 8.0, 1 mM DTT, 0.1 mg/mL BSA,
                                             0.005  Triton X-100. Final concentrations 0.5 μg/mL GDH (10 nM), 400 μM
                                             NADP+, 10 mM glutamate. Incubation time 45 minutes. fluorescence NIH-PA Author Manuscript




                                             NADPH produced monitored excitation 355 nm emission 486 nm.

                                             GK assayed buffer 50 mM Tris, pH 7.5, 50 mM KCl, 2 mM MgCl2 0.1
                                             mg/mL BSA. Final concentrations 1.5 ng/mL GK (130 pM), 7 μM GMP, 10 μM
                                             ATP. Incubation time 20 minutes, ADP GDP produced GK                                              detected Transcreener ADP detection mix (Cisbio), AdSS.

                                             NMT assayed buffer 50 mM Tris, pH 7.5, 6.25 mM NaCl, 0.625 mM
                                             MgCl2, 10  BSA, 0.005  Triton X-100. Final concentrations 1.5 μg/mL NMT
                                             (30 nM), 15 uM myristoyl-CoA, 90 uM GSSYSRKNK, synthetic peptide obtained
                                             Peptides International GenScript order parameters 85  purity                                              N- C-terminal modifications. peptide based N-terminal sequence                                              adenylate kinase 2, substrate N-myristoyltransferase P. falciparum vivo [34].
                                             Incubation time 45 minutes 30 °C, ThioGlo [35] added final


                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                             Page 5


                                             concentration 15 μM detect free –SH groups CoA produced NMT. ThioGlo
                                             fluorescence monitored excitation 360 nm emission 540 nm.
NIH-PA Author Manuscript




                                             OMPDC assayed buffer 100 mM Tris, pH 8.0, 50 mM NaCl, 1 mM MgCl2,
                                             1 mM DTT, 0.3 mg/mL BSA. Final concentrations 3 ng/mL OMPDC (77 pM), 2
                                             μM OMP, 1 μM ATP, 1 μg/mL human CMP kinase [36], used convert
                                             UMP (produced OMPDC) + ATP UDP + ADP. Incubation time 180 minutes,
                                             ADP detected Transcreener ADP detection mix (Cisbio),                                              AdSS.

                                             SAHH assayed buffer 50 mM potassium phosphate, pH 8.0. Final concentrations
                                             5 μg/mL SAHH (100 nM), 4 μM S-adenosylhomocysteine, 2.5 μg/mL adenosine
                                             deaminase P. falciparum (added consume adenosine produced SAHH,
                                             promoting continued progress forward reaction). Incubation time 90 minutes,
                                             ThioGlo [35] added final concentration 25 μM detect free –SH
                                             groups homocysteine produced SAHH. ThioGlo fluorescence monitored                                              excitation 360 nm emission 540 nm. SAHH screen unique                                              compounds initially tested single concentration 8.3 μM;  initial hits
                                             defined compounds inhibiting SAHH ≥25  concentration.

                              3. Results
NIH-PA Author Manuscript




                              3.1. Identification antimalarial compounds
                                             identified set 5,655 compounds inhibit growth P. falciparum erythrocytes
                                             described [21]. ~7,500 primary screen hits tested 8-point dose-response curves
                                             reconfirmation antimalarial activity EC50 value determination drug-
                                             resistant strains: sulfadoxine-resistant 3D7 strain multi-drug resistant W2 strain
                                             (resistant chloroquine, quinine, pyrimethamine, sulfadoxine, cycloguanil). Known
                                             inhibitors compound collection (e.g., artemisinin, mefloquine, dihydrofolate reductase
                                             inhibitors, quinine) identified, providing internal validation assay sensitivity.
                                             Counterscreens included fluorescence quencher assessment cytotoxicity Huh7
                                             human hepatocellular carcinoma cell line. Compounds EC50 < 1.25 μM P.
                                             falciparum 3d7 W2 strains selectivity index (SI) Huh7 cell line                                              5-fold did exhibit fluorescence quenching retained study.

                              3.2. Choline kinase
                                             CK catalyzes step synthesis phosphatidylcholine, essential                                              intraerythrocytic growth Plasmodium parasite [26, 37, 38]. Km CK choline
                                             determined ~200 μM, consistent value 140 μM reported [26]. NIH-PA Author Manuscript




                                             chemical inhibitor hexadecyltrimethylammonium bromide (HDTAB) used                                              positive control CK inhibition [37];  physicochemical properties HDTAB
                                             interfered homogeneous time resolved fluorescence (HTRF) signal detection.

                                             listed Table 2, CK screen resulted 69 hits 1.2  hit rate. IC50 values ranged
                                             0.06 μM 11 μM P. falciparum EC50 values ranged 0.013 μM 1.25
                                             μM. 23 powders available reconfirmation powders, reconfirmed                                              triplicate IC50 values ranging 2.9 μM 19.0 μM. Corresponding P. falciparum
                                             EC50 values 10-fold potent. hits identified                                               Supplementary Table S1), compound CK-1  3-chlorobenzothiophene amide; shown                                              Figure 1A) chemically tractable structure suitable starting point                                              chemical optimization. CK-2 CK-3 (Fig. 1A) analogs scaffold.                                              activities enzyme weaker (20-fold) cell-based activities, rank orders



                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                          Page 6


                                             potency compounds cell-based target-based
                                             assays.
NIH-PA Author Manuscript




                              3.3. S-Adenosylhomocysteine hydrolase
                                             SAHH, component methylation cycle methyl groups donated lipids,
                                             nucleic acids, proteins, molecules, certainly essential highly
                                             druggable (Table 1). similarity parasite human active sites concern,                                              residue adenosine binding site – Cys59 PfSAHH, Thr60 HsSAHH –
                                             differing [39]. Km SAHH S-adenosylhomocysteine                                              determined ~2 μM, close literature value 1.2 μM [24]. SAHH screen
                                             resulted 38 hits hit rate 0.68  (Table 2). 20 powders 38 hits                                              available,  seven compounds reconfirmed dose-response format                                              triaged based overlap target screens (AdSS, , suggesting                                              promiscuous inhibitors. IC50 values ranged 0.1 μM 9.1 μM                                              corresponding P. falciparum EC50 values ranged 0.9 μM 7.6 μM.                                              reconfirmed specific hits identified (Supplementary Table S1), SAHH-1 (Fig. 1B)                                              interesting 8-hydroxyquinoline-based hit serve potential starting point                                              medicinal chemistry. hits tool compounds,                                              chemically attractive drug discovery, include SAHH-2, quinazosin, known
                                             vasodilator alpha-1 adrenergic receptor target [40] SAHH-3, known                                              phanquinone, antimicrobial agent [41].
NIH-PA Author Manuscript




                              3.4. Enzymes involved nucleotide metabolism (AdSS, dUTPase, GK, OMPDC)
                                             AdSS, purine salvage pathway, obtained Km values 14 μM IMP,
                                             105 μM GTP, 0.05 mM aspartate, somewhat different previously
                                             reported values 22.8 μM, 4.8 μM, 1.4 mM, respectively [29]. AdSS screen
                                             resulted 9 hits 0.2  hit rate (Table 2). Hadacidin used positive control
                                             inhibitor [42], IC50 value 62 μM. hits, available powders                                              reconfirmed. compounds triaged inhibited SAHH activity,
                                             leaving 3 candidate AdSS inhibitors (Supplementary Table S1).                                               compounds unlikely starting points medicinal chemistry chemically labile
                                             functionalities sulfonylureas (AdSS-1), imines derived aldehydes (AdSS-2)
                                             quaternary aromatic amines (AdSS-3). AdSS-1 (Fig. 1C), N-sulfonylurea,                                              useful tool compound;  publicly available information cites cytostatic
                                             mechanism action human cells  PubChem: 120394059 120394064). AdSS-2 (Fig.
                                             1C), benzyaldehydederived imine, relatively specific malaria inhibition;                                              compound useful tool compound AdSS.
NIH-PA Author Manuscript




                                             GK selected target based involvement nucleic acid synthesis. GK converts
                                             (d)GMP (d)GDP, turn used make (d)GTP, essential nucleic
                                             acid synthesis. likely essentiality GK   doubt, Plasmodium
                                             thymidylate kinase (2.7.4.9) convert dGMP dGDP [43, 44]. additional
                                             enzyme, ribonucleoside-diphosphate reductase (1.17.4.1), convert dGDP GDP. 
                                             GK blocked, (d)GDP dGMP.                                               expression GK liver stage Plasmodium life cycle [45] suggests possible
                                             importance stage possible usefulness target complementing                                              prominent erythrocyte stages.

                                             Km P. vivax GK GMP 3.5 μM, lower value 22 μM reported                                              P. falciparum GK [28]. GK screen resulted 17 hits (0.3  hit rate) shown                                              Table 2. positive control iodoacetamide IC50 value 36.5 μM assay
                                             conditions used. range guanylate kinase IC50 values 17 hits 0.5 μM– 7.8


                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                               Page 7


                                             μM. Seven compounds available powders; reconfirmed 3 showing
                                             specificity PvGK (Supplementary Table S1) shown Figure 1D. GK-1                                              nitro groups does represent chemically attractive scaffold unless analogs
NIH-PA Author Manuscript




                                             nitro groups remain active.  compound relatively specific
                                             does appear promiscuous inhibitor historical HTS run GNF.
                                             Interestingly, screens overlapping activity pathogen-based screens
                                             related presence nitro groups. GK-2 GK-3 (Figure 1D)                                              potentially useful tool compounds interrogate malaria parasite biology confirm
                                             PvGK target compounds.  GK-2 ammonium salt                                              low likelihood oral bioavailability, GK-3 imine napthoquinone                                              stability issues trap electrophiles;  ideal starting point medical
                                             chemistry efforts.

                                             OMPDC pyrimidine biosynthesis enzyme downstream validated target
                                             dihydroorotate dehydrogenase [46]. approximate Km orotidine 5′-monophosphate
                                             (OMP) ~0.2 μM, lower previously reported value 13.4 μM (PMID
                                             15683248). OMPDC screen resulted 26 hits approximate hit rate 0.5 
                                             (Table 2). IC50 values ranged 0.22 μM 10 μM P. falciparum EC50 values
                                             ranged 0.176 μM 1.7 μM. 11 powders available reconfirmation                                              reconfirmed, identified fluorescence quenchers                                              false positives. Unfortunately, attractive hit chemical standpoint, OMPDC-1
NIH-PA Author Manuscript




                                             (Fig. 1E), weak inhibitor OMPDC (IC50 19.7 μM), potent                                              cellular P. falciparum assay. OMPDC-1 useful tool compound investigation
                                             effects parasite OMPDC inhibition.

                                             dUTPase protects DNA integrity preventing buildup dUTP conversion                                              dUMP, converted dTTP used DNA synthesis [47]. Km                                              dUTPase dUTP measured 4.5 μM, somewhat higher literature value                                              1.9 μM [48]. positive control used dUTPase inhibition 2′-deoxy-5′-O-
                                             (triphenylmethyl)uridine, IC50 value 2.4 μM assay conditions.
                                             dUTPase screen resulted 95 hits (3.1  hit rate) positive control inhibitor
                                             performed expected. 91 compounds available powders retested dose-
                                             response reconfirmation screen IC50 values. parallel, hits counterscreened                                              potential inhibit components PPi detection kit Lonza.                                              counterscreen tested putative hits ability inhibit direct detection ~5 μM PPi,
                                             using detection reagents primary dUTPase. positive control showed                                              expected inhibition profile dUTPase assay inhibition counterscreen.
                                              hits inhibitors counterscreen. conclusion, did                                              identify hits inhibitors dUTPase.
NIH-PA Author Manuscript




                              3.5. Enzymes involved pathways adding lipid groups proteins (NMT FPPS)
                                             NMT transfers myristate (saturated C14 fatty acid) groups N-terminal glycine residues                                              substrate proteins, increasing hydrophobicity promoting associations                                              membranes proteins [49]. NMT Km 7 μM myristoyl-CoA 21 μM
                                             synthetic peptide GSSYSRKNK.

                                             positive control inhibitor NMT inhibition, aurintricarboxylate, IC50 ~3
                                             μM. NMT screen resulted 7 hits overall hit rate 0.2 . positive control
                                             inhibitor, aurintricarboxylate, performed expected. 5 compounds available                                              reconfirmed inihibition. NMT-1 (Fig. 1F) did score past screens performed                                              GNF, suggesting specific activity NMT. single nitro group,                                              concomitant risk mutagenic potential [50], compound useful tool
                                             compound validate NMT viable drug target. structures 

                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                            Page 8


                                             chemically attractive drug discovery, contain structural alerts,                                              nitro groups NMT-1 NMT-3 ammonium salts NMT-2, 4, 5                                               Supplementary Table S1), possibly used tool compounds NMT
NIH-PA Author Manuscript




                                             inhibition.

                                             FPPS involved post-translational modification proteins protein
                                             farnesylation. FPPS produces farnesyl diphosphate  k  farnesyl pyrophosphate FPP),
                                             used protein farnesyltransferase (PFT), validated target Plasmodium
                                             [51], attachment farnesyl groups proteins. Km’s FPPS 8 μM geranyl
                                             diphosphate 9 μM isopentenyl diphosphate. positive control inhibitor (1-
                                             hydroxy-2-phenylethylidene)bis-phosphonic acid IC50 7.7 μM FPPS                                              EC50 value ~7.05 μM P. falciparum vitro. FPPS screen resulted 147
                                             hits. Unfortunately, exception positive control, (1-hydroxy-2-
                                             phenylethylidene)bis-phosphonic acid, hits reconfirmed FPPS assay                                              hits counterscreen (conducted described dUTPase). conclusion,                                              compounds hit specificity FPPS exception positive control
                                             inhibitor.

                              3.6. Glutamate dehydrogenase
                                             GDH provides NADPH biosynthesis glutathione reductase, oxidative stress-
                                             fighting enzyme thought essential [25]. contrast mammalian GDH enzyme,
NIH-PA Author Manuscript




                                             PfGDH highly specific NADP+ NADPH, suggesting exploitable differences
                                             mammalian parasite enzymes. Km’s estimated 16 μM                                              NADP+ 0.8 mM glutamate, consistent literature values 20 μM 1 mM,
                                             respectively [25]. GDH screen resulted 164 hits, 2.9  hit rate;  activity
                                             hits GDH weak. 78 powders available tested                                              reconfirmation hits reconfirmed assay conditions used. decrease                                              assay stringency increase sensitivity inhibitors, concentration substrate
                                             [NADP+] reduced 400 μM 50 μM, hits reconfirmed. conclusion,
                                             hits identified GDH.

                              4. Discussion
                                             availability large compound collections automated robotic systems ultra high-
                                             throughput screening commonplace pharmaceutical companies,                                              frequent academia. collection antimalarial chemical inhibitors
                                             identified screening non-proprietary compound collections. application,                                              attempted link antimalarial compounds possible protein targets.                                              cell-active compounds tested high-throughput assays enzymes believed NIH-PA Author Manuscript




                                             potential drug targets based considerations essentiality, druggability,
                                             selectivity, amenability high-throughput screening (section 2.2 Table 1).                                              enzymes included involved nucleotide metabolism (AdSS, dUTPase, GK,                                              OMPDC) attachment lipid groups proteins (NMT FPPS)                                              components key metabolic pathways (CK, GDH, SAHH).                                              unable detect inhibitors dUTPase, FPPS GDH, identified inhibitors AdSS,
                                             GK, OMPDC, NMT, CK, SAHH potential starting points medicinal chemistry                                              tool compounds Plasmodium enzymes. view, results validate
                                             disprove wisdom target selection strategy. disappointed                                              potent inhibitors enzymes chosen;  screen larger chemical library
                                             retrieved compounds suitable development leads good activity
                                             enzymes parasite cells.




                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                              Page 9


                                             IC50 values preliminary hits enzymes checked repurchased compounds
                                             (Table 3 Supplementary Table S1). Reversible inhibitors generally act                                              intracellular targets IC50 lower EC50 parasite.  NIH-PA Author Manuscript




                                             compound concentrations target-based hits required inhibit enzyme activity
                                             higher concentrations needed inhibit P. falciparum growth.                                              number possible explanations cellular enzymatic discrepancy.                                               targets inhibited antimalarial compounds                                               primary, target compound; inhibition protein  non-protein
                                             targets) contribute cellular activity [52]. Second, possible mechanism
                                             compound affecting parasitic activity completely unrelated                                              biochemical activity reported   EC50 values lower relative                                              biochemical IC50 values test compound accumulates higher concentrations inside
                                             parasite. Lastly, comparing enzyme activity antimalarial activity                                              particularly helpful, given unavoidable differences intracellular vitro
                                             conditions (e.g. substrate concentrations), unless comparing structure activity
                                             relationships (SAR) set chemically related analogs relative enzyme                                              antimalarial inhibition. Derivation pharmacophore correlation enzyme-
                                             based parasite-based inhibition needed identify meaningful SAR correlations                                              link target hits observed cell-based phenotype. highest priority follow
                                             enzyme inhibitors IC50’s < EC50’s, investigations associations                                              high-value compounds targets prove worthwhile chemically validate targets.
NIH-PA Author Manuscript




                                             targets (dUTPase, GDH FPPS) lacked hits compounds tested.                                              possible enzymes essential parasite assay conditions.
                                             Alternatively, broader library antimalarial compounds selected
                                             lacking chemical composition capable inhibiting enzymes.
                                             Regarding possibility, enzymes predicted moderate high
                                             druggability according silico methods  Table 1). approach offered test                                              silico predictions suggested benefit refinement.

                                             test inhibition particular biochemical target causal antimalarial
                                             activity, approaches possible. include:   allowing cultures evolve
                                             resistance compound determining mutations occur gene                                              presumed target [53]; (b) studying compounds chemically related original hit                                              looking correlation IC50’s presumed target EC50’s                                              parasite [54]; (c) determining overexpression putative target overcomes                                              inhibition observed presence compound [55]  genetic manipulation                                              Plasmodium challenging); (d) detecting buildup presumed target’s substrate
                                             depletion product extracts compound-treated cells [56–58], NIH-PA Author Manuscript




                                             determining parasite growth restored supplementation media                                              missing product [59]; (e) using compounds affinity probes isolate target
                                             proteins cell lysates [60].

                                             Despite extensive screening work reported  mechanisms action 5,655
                                             antimalarial compounds generally remain elusive.  modifications present
                                             approach lead greater success identifying mechanisms action. example,
                                             studying compounds EC50’s >1.25 μM enable discovery weak
                                             activity parasite EC50/IC50 data strongly point particular target.
                                             Furthermore, considering roughly 2 5  organism’s genes legitimate
                                             potential drug targets [61], number proteins tested relatively small                                              labor-intensive requirement optimizing separate biochemical assay protein.
                                             generic method assessing compound-protein binding, thermal melting [32]                                              Surface Plasmon Resonance [62], allow proteins studied simultaneously,


                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                                               Page 10


                                             increasing odds identified likely targets antiparasitic
                                             compounds. Finally, possible similar screening efforts instead focus                                              finding new scaffolds previously validated targets.
NIH-PA Author Manuscript




                                             conclusion, data support original proposition target-based drug
                                             discovery accelerated starting cell-active compounds. early                                              say enzyme-compound associations identified screens represent
                                             compound’s true mechanism action inhibiting parasite growth, compounds
                                             utility exploring biology surrounding possible targets.                                              tool compounds employed basic studies enzyme function pathway biology
                                             starting points structure-activity relationship (SAR) selectivity studies.
                                             Screens kind performed yield valuable information                                              result identification biochemically potent lead compounds drug development.

                              Supplementary Material
                                             Refer Web version PubMed Central supplementary material.


                              Acknowledgments
                                             efforts possible combination pharmaceutical resources (Novartis), funding                                              Medicines Malaria Venture (MMV) partnership academia  University Washington). thank
NIH-PA Author Manuscript




                                             Thierry Diagana Novartis Institute Tropical Diseases (NITD) Singapore help planning project
                                             critical review manuscript, Christophe Bodenreider NITD sharing unpublished data.


                              References
                                             1. Valderramos SG, Fidock DA. Transporters involved resistance antimalarial drugs. Trends
                                                Pharmacol Sci. 2006; 27:594–601. [PubMed: 16996622]
                                             2. Ekland EH, Fidock DA. vitro evaluations antimalarial drugs relevance clinical
                                                outcomes. Int J Parasitol. 2008; 38:743–7. [PubMed: 18406409]
                                             3. Nkrumah LJ, Riegelhaupt PM, Moura P, et al. Probing multifactorial basis Plasmodium
                                                falciparum quinine resistance: evidence strain-specific contribution sodium-proton
                                                exchanger PfNHE. Mol Biochem Parasitol. 2009; 165:122–31. [PubMed: 19428659]
                                             4. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute quinine resistance                                                 enhance mefloquine artemisinin sensitivity Plasmodium falciparum. Mol Microbiol. 2005;
                                                57:913–26. [PubMed: 16091034]
                                             5. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing
                                                pfmdr1 copy number plasmodium falciparum malaria heightens susceptibility mefloquine,
                                                lumefantrine, halofantrine, quinine, artemisinin. J Infect Dis. 2006; 194:528–35. [PubMed:
NIH-PA Author Manuscript




                                                16845638]
                                             6. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance Plasmodium falciparum malaria
                                                parasites conferred pfcrt mutations. Science. 2002; 298:210–3. [PubMed: 12364805]
                                             7. Eastman RT, Fidock DA. Artemisinin-based combination therapies: vital tool efforts                                                 eliminate malaria. Nat Rev Microbiol. 2009; 7:864–74. [PubMed: 19881520]
                                             8. Dondorp  Nosten F, Yi P, et al. Artemisinin resistance Plasmodium falciparum malaria. N
                                                Engl J Med. 2009; 361:455–67. [PubMed: 19641202]
                                             9. Lim P, Alker AP, Khim N, et al. Pfmdr1 copy number arteminisin derivatives combination
                                                therapy failure falciparum malaria Cambodia. Malar J. 2009; 8:11. [PubMed: 19138391]
                                             10. White NJ. Qinghaosu (artemisinin): price success. Science. 2008; 320:330–4. [PubMed:
                                                  18420924]
                                             11. Odom AR, Van Voorhis WC. Functional genetic analysis Plasmodium falciparum
                                                  deoxyxylulose 5-phosphate reductoisomerase gene. Mol Biochem Parasitol. 2010; 170:108–11.
                                                  [PubMed: 20018214]



                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                                    Page 11


                                             12. Slavic K, Straschil U, Reininger L, et al. Life cycle studies hexose transporter                                                  Plasmodium species genetic validation essentiality. Mol Microbiol. 2010
                                             13. Vaughan  O’Neill MT, Tarun  et al. Type II fatty acid synthesis essential NIH-PA Author Manuscript




                                                 malaria parasite late liver stage development. Cell Microbiol. 2009; 11:506–20. [PubMed:
                                                 19068099]
                                             14. Sasaki N, Hirai M, Maeda K, et al. Plasmodium HU homolog, binds plastid DNA
                                                 sequence-independent manner, essential parasite’s survival. FEBS Lett. 2009; 583:1446–
                                                 50. [PubMed: 19358847]
                                             15. Gunther S, Matuschewski K, Muller S. Knockout studies reveal important role Plasmodium
                                                 lipoic acid protein ligase A1 asexual blood stage parasite survival. PLoS  2009; 4:e5510.
                                                 [PubMed: 19434237]
                                             16. Sijwali PS, Koo J, Singh N, Rosenthal PJ. Gene disruptions demonstrate independent roles                                                  falcipain cysteine proteases Plasmodium falciparum. Mol Biochem Parasitol. 2006;
                                                 150:96–106. [PubMed: 16890302]
                                             17. El Bissati K, Zufferey R, Witola WH, Carter NS, Ullman B, Ben Mamoun C. plasma
                                                 membrane permease PfNT1 essential purine salvage human malaria parasite
                                                 Plasmodium falciparum. Proc Natl Acad Sci U S  2006; 103:9286–91. [PubMed: 16751273]
                                             18. Omara-Opyene AL, Moura PA, Sulsona CR, et al. Genetic disruption Plasmodium
                                                 falciparum digestive vacuole plasmepsins demonstrates functional redundancy. J Biol Chem.
                                                 2004; 279:54088–96. [PubMed: 15491999]
                                             19. Krnajski  Gilberger TW, Walter RD, Cowman AF, Muller S. Thioredoxin reductase essential
                                                 survival Plasmodium falciparum erythrocytic stages. J Biol Chem. 2002; 277:25970–5.
NIH-PA Author Manuscript




                                                 [PubMed: 12004069]
                                             20. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs bad bugs: confronting challenges
                                                 antibacterial discovery. Nat Rev Drug Discov. 2007; 6:29–40. [PubMed: 17159923]
                                             21. Plouffe D, Brinker  McNamara C, et al. silico activity profiling reveals mechanism                                                  action antimalarials discovered high-throughput screen. Proc Natl Acad Sci U S  2008;
                                                 105:9059–64. [PubMed: 18579783]
                                             22. Aguero F, Al-Lazikani B, Aslett M, et al. Genomic-scale prioritization drug targets: TDR
                                                 Targets database. Nat Rev Drug Discov. 2008; 7:900–7. [PubMed: 18927591]
                                             23. Menz RI, Cinquin O, Christopherson RI. identification, cloning functional expression                                                  gene encoding orotidine 5′-monophosphate (OMP) decarboxylase Plasmodium
                                                 falciparum. Ann Trop Med Parasitol. 2002; 96:469–76. [PubMed: 12194707]
                                             24. Nakanishi M, Iwata  Yatome C, Kitade Y. Purification properties recombinant
                                                 Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. J Biochem. 2001; 129:101–5.
                                                 [PubMed: 11134963]
                                             25. Wagner JT, Ludemann H, Farber PM, Lottspeich F, Krauth-Siegel RL. Glutamate dehydrogenase,
                                                 marker protein Plasmodium falciparum--cloning, expression characterization                                                  malarial enzyme. Eur J Biochem. 1998; 258:813–9. [PubMed: 9874251]
                                             26. Choubey V, Guha M, Maity P, et al. Molecular characterization localization Plasmodium
NIH-PA Author Manuscript




                                                 falciparum choline kinase. Biochim Biophys Acta. 2006; 1760:1027–38. [PubMed: 16626864]
                                             27. Gunaratne RS, Sajid M, Ling  Tripathi R, Pachebat JA, Holder AA. Characterization N-
                                                 myristoyltransferase Plasmodium falciparum. Biochem J. 2000; 348(Pt 2):459–63. [PubMed:
                                                 10816442]
                                             28. Kandeel M, Nakanishi M, Ando T, et al. Molecular cloning, expression, characterization                                                  mutation Plasmodium falciparum guanylate kinase. Mol Biochem Parasitol. 2008; 159:130–3.
                                                 [PubMed: 18374996]
                                             29. Jayalakshmi R, Sumathy K, Balaram H. Purification characterization recombinant
                                                 Plasmodium falciparum adenylosuccinate synthetase expressed Escherichia coli. Protein Expr
                                                 Purif. 2002; 25:65–72. [PubMed: 12071700]
                                             30. Whittingham JL, Leal  Nguyen C, et al. dUTPase platform antimalarial drug design:
                                                 structural basis selectivity class nucleoside inhibitors. Structure. 2005; 13:329–38.
                                                 [PubMed: 15698576]




                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                                 Page 12


                                             31. Phillips MA, Coffino P, Wang CC. Cloning sequencing ornithine decarboxylase gene
                                                 Trypanosoma brucei. Implications enzyme turnover selective difluoromethylornithine
                                                 inhibition. J Biol Chem. 1987; 262:8721–7. [PubMed: 3036823]
NIH-PA Author Manuscript




                                             32. Crowther GJ, Napuli AJ, Thomas AP, et al. Buffer optimization thermal melt assays                                                  Plasmodium proteins detection small-molecule ligands. Journal Biomolecular Screening.
                                                 2009; 14:700–707. [PubMed: 19470714]
                                             33. Crowther GJ, P, Rodenbough PP, et al. Use thermal melt curves assess quality                                                  enzyme preparations. Anal Biochem. 2010; 399:268–75. [PubMed: 20018159]
                                             34. Rahlfs S, Koncarevic S, Iozef R, et al. Myristoylated adenylate kinase-2 Plasmodium falciparum
                                                 forms heterodimer myristoyltransferase. Mol Biochem Parasitol. 2009; 163:77–84.
                                                 [PubMed: 18973776]
                                             35. Wright SK, Viola  Evaluation methods quantitation cysteines proteins. Anal
                                                 Biochem. 1998; 265:8–14. [PubMed: 9866701]
                                             36. Liou JY, Dutschman GE, Lam W, Jiang  Cheng YC. Characterization human UMP/CMP
                                                 kinase phosphorylation D- L-form deoxycytidine analogue monophosphates. Cancer
                                                 Res. 2002; 62:1624–31. [PubMed: 11912132]
                                             37. Choubey V, Maity P, Guha M, et al. Inhibition Plasmodium falciparum choline kinase                                                  hexadecyltrimethylammonium bromide: possible antimalarial mechanism. Antimicrob Agents
                                                 Chemother. 2007; 51:696–706. [PubMed: 17145794]
                                             38. Ancelin ML, Vial HJ. Quaternary ammonium compounds efficiently inhibit Plasmodium
                                                 falciparum growth vitro impairment choline transport. Antimicrob Agents Chemother.
                                                 1986; 29:814–20. [PubMed: 3524430]
NIH-PA Author Manuscript




                                             39. Tanaka N, Nakanishi M, Kusakabe Y, et al. Crystal structure S-adenosyl-L-homocysteine
                                                 hydrolase human malaria parasite Plasmodium falciparum. J Mol Biol. 2004; 343:1007–
                                                 17. [PubMed: 15476817]
                                             40. Greenslade FC, Scott CK, Newquist KL, Krider KM, Chasin M. Heterogeneity biochemical
                                                 actions vasodilators. J Pharm Sci. 1982; 71:94–100. [PubMed: 6276530]
                                             41. Mett H, Gyr K, Zak O, Vosbeck K. Duodeno-pancreatic secretions enhance bactericidal activity                                                  antimicrobial drugs. Antimicrob Agents Chemother. 1984; 26:35–8. [PubMed: 6236746]
                                             42. Raman J, Mehrotra S, Anand RP, Balaram H. Unique kinetic mechanism Plasmodium
                                                 falciparum adenylosuccinate synthetase. Mol Biochem Parasitol. 2004; 138:1–8. [PubMed:
                                                 15500910]
                                             43. Kandeel M, Kitade Y. Molecular characterization, heterologous expression kinetic analysis                                                  recombinant Plasmodium falciparum thymidylate kinase. J Biochem. 2008; 144:245–50.
                                                 [PubMed: 18477629]
                                             44. Kandeel M, Kitamura Y, Kitade Y. exceptional properties Plasmodium deoxyguanylate
                                                 pathways potential area metabolic drug discovery studies. Nucleic Acids Symp Ser
                                                 (Oxf). 2009:39–40.
                                             45. Tarun  Peng X, Dumpit RF, et al. combined transcriptome proteome survey malaria
                                                 parasite liver stages. Proc Natl Acad Sci U S  2008; 105:305–10. [PubMed: 18172196]
NIH-PA Author Manuscript




                                             46. Gujjar R, Marwaha  El Mazouni F, et al. Identification metabolically stable
                                                 triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor antimalarial activity                                                  mice. J Med Chem. 2009; 52:1864–72. [PubMed: 19296651]
                                             47. Nguyen C, Kasinathan G, Leal-Cortijo  et al. Deoxyuridine triphosphate nucleotidohydrolase                                                  potential antiparasitic drug target. J Med Chem. 2005; 48:5942–54. [PubMed: 16161998]
                                             48. Quesada-Soriano  Leal  Casas-Solvas JM, et al. Kinetic thermodynamic characterization                                                  dUTP hydrolysis Plasmodium falciparum dUTPase. Biochim Biophys Acta. 2008; 1784:1347–
                                                 55. [PubMed: 18586121]
                                             49. Gelb MH, Van Voorhis WC, Buckner FS, et al. Protein farnesyl N-myristoyl transferases:
                                                 piggyback medicinal chemistry targets development antitrypanosomatid antimalarial
                                                 therapeutics. Mol Biochem Parasitol. 2003; 126:155–63. [PubMed: 12615314]
                                             50. Orsiere T, Meo M, Rathelot P, et al. Implication nitro group reduction mutagenic                                                  chromosome damaging activities 22 new 5-nitroisoquinolines Salmonella mutagenicity



                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                                  Page 13


                                                 test cytokinesis-blocked micronucleus assay. Food Chem Toxicol. 2003; 41:275–90.
                                                 [PubMed: 12480303]
                                             51. Fletcher S, Cummings CG, Rivas K, et al. Potent, Plasmodium-selective farnesyltransferase
NIH-PA Author Manuscript




                                                 inhibitors arrest growth malaria parasites: structure-activity relationships                                                  ethylenediamine-analogue scaffolds homology model validation. J Med Chem. 2008;
                                                 51:5176–97. [PubMed: 18686940]
                                             52. Hopkins AL. Network pharmacology: paradigm drug discovery. Nat Chem Biol. 2008;
                                                 4:682–90. [PubMed: 18936753]
                                             53. Dharia NV, Sidhu AB, Cassera MB, et al. Use high-density tiling microarrays identify
                                                 mutations globally elucidate mechanisms drug resistance Plasmodium falciparum.
                                                 Genome Biol. 2009; 10:R21. [PubMed: 19216790]
                                             54. Mukkamala D, JH, Cass LM, Chang TK, Oldfield E. Bisphosphonate inhibition                                                  Plasmodium farnesyl diphosphate synthase general method predicting cell-based activity
                                                 enzyme data. J Med Chem. 2008; 51:7827–33. [PubMed: 19053772]
                                             55. Luesch H, Wu TY, Ren P, Gray NS, Schultz PG, Supek F. genome-wide overexpression screen
                                                 yeast small-molecule target identification. Chem Biol. 2005; 12:55–63. [PubMed:
                                                 15664515]
                                             56. Hankins  Gillespie JR, Aikenhead K, Buckner FS. Upregulation sterol C14-demethylase
                                                 expression Trypanosoma cruzi treated sterol biosynthesis inhibitors. Mol Biochem
                                                 Parasitol. 2005; 144:68–75. [PubMed: 16165233]
                                             57. Seymour KK, Lyons SD, Phillips L, Rieckmann KH, Christopherson RI. Cytotoxic effects                                                  inhibitors novo pyrimidine biosynthesis Plasmodium falciparum. Biochemistry. 1994;
NIH-PA Author Manuscript




                                                 33:5268–74. [PubMed: 7909690]
                                             58. Vial HJ, Thuet MJ, Ancelin ML, Philippot JR, Chavis C. Phospholipid metabolism new target
                                                 malaria chemotherapy. Mechanism action D-2-amino-1-butanol. Biochem Pharmacol.
                                                 1984; 33:2761–70. [PubMed: 6431995]
                                             59. Roberts F, Roberts CW, Johnson JJ, et al. Evidence shikimate pathway apicomplexan
                                                 parasites. Nature. 1998; 393:801–5. [PubMed: 9655396]
                                             60. Kato N, Sakata T, Breton G, et al. Gene expression signatures small-molecule compounds link
                                                 protein kinase Plasmodium falciparum motility. Nat Chem Biol. 2008; 4:347–56. [PubMed:
                                                 18454143]
                                             61. Hopkins AL, Groom CR. druggable genome. Nat Rev Drug Discov. 2002; 1:727–30.
                                                 [PubMed: 12209152]
                                             62. Piliarik M, Vaisocherova H, Homola J. Surface plasmon resonance biosensing. Methods Mol Biol.
                                                 2009; 503:65–88. [PubMed: 19151937]
                                             63. Hyde JE. Targeting purine pyrimidine metabolism human apicomplexan parasites. Curr
                                                 Drug Targets. 2007; 8:31–47. [PubMed: 17266529]
                                             64. Vial HJ, Wein S, Farenc C, et al. Prodrugs bisthiazolium salts orally potent antimalarials.
                                                 Proc Natl Acad Sci U S  2004; 101:15458–63. [PubMed: 15492221]
NIH-PA Author Manuscript




                                             65. Jarzyna R, Lenarcik E, Bryla J. Chloroquine potent inhibitor glutamate dehydrogenase                                                  liver kidney-cortex rabbit. Pharmacol Res. 1997; 35:79–84. [PubMed: 9149320]
                                             66. Werner C, Stubbs MT, Krauth-Siegel RL, Klebe G. crystal structure Plasmodium
                                                 falciparum glutamate dehydrogenase, putative target novel antimalarial drugs. J Mol Biol.
                                                 2005; 349:597–607. [PubMed: 15878595]
                                             67. Martin MB, Grimley JS, Lewis JC, et al. Bisphosphonates inhibit growth Trypanosoma
                                                 brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, Plasmodium
                                                 falciparum: potential route chemotherapy. J Med Chem. 2001; 44:909–16. [PubMed:
                                                 11300872]




                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                        Page 14
NIH-PA Author Manuscript




                                             Figure 1.
                                             Chemically tractable inhibitors discovered biochemical screens. Abbreviations refer
                                             enzymes inhibited:   choline kinase (CK), (B) S-adenosylhomocysteine hydrolase
                                             (SAHH), (C) adenylosuccinate synthetase (AdSS), (D) guanylate kinase (GK), (E) OMP
                                             decarboxylase (OMPDC), (F) N-myristoyltransferase (NMT).
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                             Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                                                Page 15




                                                                                           Table 1
                           Selection promising drug targets biochemical screens
NIH-PA Author Manuscript




                            Enzyme (PlasmoDB ID)                       Essentiality                  Druggability score*   Genome-wide percentile ranking**

                            Adenylosuccinate synthase (PF13_0287)           purine salvage                0.8                        99.5 
                                                                            pathway,                                                                             essential                                                                             Plasmodium                                                                             synthesize purines                                                                             novo [63].

                            Choline kinase (PF14_0020)                      Chemical validation                0.6                        97.9 
                                                                            Kennedy pathway                                                                             phosphatidylcholine
                                                                            synthesis suggested                                                                             work Henri Vial
                                                                            [64].

                            dUTPase (PF11_0282)                             dUTPase likely                0.6                        99.8 
                                                                            essential                                                                             prevents buildup                                                                             dUTP makes dUMP
                                                                            dTTP synthesis [47].
                            Farnesyl pyrophosphate synthase                 protein                         0.8                        99.3 
                            (PVX_092040)                                    farnesyltransferase                                                                             valid drug target                                                                             Plasmodium [51], FPPS
NIH-PA Author Manuscript




                                                                                                                                                        supplies                                                                             substrate PFT.                                                                             recent paper reported                                                                             ability predict cell-
                                                                            killing activity                                                                             bisphosphonates’
                                                                            inhibition FPPS [54].
                            Glutamate dehydrogenase (PF14_0164)             Thought major                 0.8                        99.7 
                                                                            source NADPH                                                                             glutathione reductase,
                                                                            thought                                                                             essential [65].                                                                             based fact
                                                                            Plasmodium                                                                             “exposed multiple
                                                                            oxidative stress                                                                             high metabolic rate,                                                                             degradation heme                                                                             reactive oxygen species
                                                                            imposed host
                                                                            immune ? [66].

                            Guanylate kinase (PVX_099895)                   Based metabolic                    0.2                        98.4 
                                                                            maps, guanylate kinase
NIH-PA Author Manuscript




                                                                            appeared                                                                             route                                                                             Plasmodium convert
                                                                            GMP GDP dGMP
                                                                            dGDP.  possible
                                                                            bypass noted                                                                             text.)  expression
                                                                            liver stage [45]
                                                                            suggests importance                                                                             stage.

                            N-myristoyltransferase (PF14_0127)              argued Gelb et al.              0.8                        98.4 
                                                                            [49], “Genetic studies
                                                                            shown                                                                             NMT gene essential
                                                                            viability range                                                                             species, including
                                                                            Drosophila
                                                                            melanogaster, S.




                                                  Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                                                                  Page 16




                               Enzyme (PlasmoDB ID)                           Essentiality                   Druggability score*       Genome-wide percentile ranking**
                                                                                   cerevisiae Candida
                                                                                   albicans NIH-PA Author Manuscript




                                                                                   Cryptococcus
                                                                                   neoformans.?

                               OMP decarboxylase (PF10_0225)                       novo                     N                              98.6 
                                                                                   pyrimidine synthesis
                                                                                   pathway,                                                                                    essential                                                                                    Plasmodium                                                                                    does                                                                                    pyrimidine salvage
                                                                                   pathway [63]. 
                                                                                   chemical validation                                                                                    novo pyrimidine
                                                                                   pathway comes                                                                                    studies dihydroorotate
                                                                                   dehydrogenase [46].

                               S-adenosylhomocysteine hydrolase (PFE1050w)         methylation                   0.8                              99.9 
                                                                                   cycle blockage
                                                                                   fatal [39].

                           *
                            Druggability scores taken TDRtargets.org. Scores range 0.0 1.0, 1.0 signifying maximum druggability ~0.2 signifying
                           average score.
                           **
                              TDRtargets.org used perform multiparameter weighted search, points awarded various features considered desirable NIH-PA Author Manuscript




                           potential drug target. Percentiles computed rank-order list genes Plasmodium genome. Points awarded                            follows: 8 points gene life cycle stage (merozoite, early late ring, early late schizont, early late trophozoite)                            expression ranks quintile (80th 100th percentile) given erythrocyte life cycle stage; 4 points gene life
                           cycle stage expression 60th 80th percentile; 50 points gene genetic validation (according manual curation                            literature); 35 points gene associated publications (according automated analysis PubMed); 50 points                            gene associated crystal structures; 30 points gene 3D structural model (ModBase); 25 points                            gene lacking ortholog humans; 20 points gene lacking predicted transmembrane domain; 20 points gene coding protein
                           100 kilodaltons; 100 points gene coding enzyme; 40 points gene orthologs essential model
                           organism; 30 points gene activity assay available.
NIH-PA Author Manuscript




                                                     Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1.
                            Crowther et al.                                                                                                                            Page 17




                                                                                               Table 2
                           Screening reactions detection strategies
NIH-PA Author Manuscript




                               Enzyme (EC number)                 Chemical reactions                Detection strategy                    Control wells*

                               Adenylosuccinate synthetase (6.3.4.4)   Primary: GTP + IMP + L-           Detect GDP using Cisbio               Hadacidin [42]
                                                                       aspartate → GDP + Pi +            Transcreener ADP kit.
                                                                       adenylosuccinate
                               Choline kinase (2.7.1.32)               Primary: ATP + choline →          Detect ADP using Cisbio               choline
                                                                       ADP + phosphocholine              Transcreener ADP kit.

                               dUTPase (3.6.1.23)                      Primary: dUTP + H2O →             Detect PPi Lonza PPiLight        CAS: 14270-73-6,84472-83-3
                                                                       dUMP + PPi                        kit.

                               Farnesyl pyrophosphate synthase         Primary: geranyl diphosphate      Detect PPi Lonza PPiLight        compound 11 [67]
                               (2.5.1.−)                               + isopentenyl diphosphate →       kit.
                                                                       farnesyl diphosphate + PPi

                               Glutamate dehydrogenase (1.4.1.4)       Primary: L-glutamate + H2O        Detect NADPH fluorescence.            glutamate
                                                                       + NADP+ → 2-oxoglutarate
                                                                       + NH3 + NADPH + H+

                               Guanylate kinase (2.7.4.8)              Primary: ATP + GMP →              Detect ADP GDP using              Iodoacetamide
                                                                       ADP + GDP                         Cisbio Transcreener ADP kit.

                               N-myristoyltransferase (2.3.1.97)       Primary: myristoyl-CoA +          Detect CoA’s free –SH groups          aurintricarboxylate
                                                                       glycylpeptide → CoA + N-          ThioGlo.
NIH-PA Author Manuscript




                                                                       myristoylglycylpeptide

                               OMP decarboxylase (4.1.1.23)            Primary: OMP → UMP +              Detect ADP using Cisbio               OMP
                                                                       ATP CMP kinase: UMP +             Transcreener ADP kit.
                                                                       ATP → UDP + ADP

                               S- adenosylhomocysteine hydrolase       Primary: S-                       Detect homocysteine’s free –SH        S- adenosylhomocysteine
                               (3.3.1.1)                               adenosylhomocysteine + H2O        groups ThioGlo.
                                                                       → adenosine + homocysteine
                                                                       Adenosine deaminase:
                               